Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nikolai A. Belyakov"'
Autor:
Alexey V. Orlov, Maria O. Zolotova, Denis O. Novichikhin, Nikolai A. Belyakov, Svetlana G. Protasova, Petr I. Nikitin, Artem V. Sinolits
Publikováno v:
Biosensors, Vol 14, Iss 11, p 531 (2024)
This study presents the development of stannous chloride (SnCl2)-modified glass substrates for biomolecule immobilization and their application in fabricating sensor chips for label-free interferometric biosensors. The glass modification process was
Externí odkaz:
https://doaj.org/article/2215567a8fc940fdaf6ce6026bd6dc5f
Autor:
Anna N. Gabashvili, Nelly S. Chmelyuk, Vera V. Oda, Maria K. Leonova, Viktoria A. Sarkisova, Polina A. Lazareva, Alevtina S. Semkina, Nikolai A. Belyakov, Timur R. Nizamov, Petr I. Nikitin
Publikováno v:
Pharmaceutics, Vol 15, Iss 10, p 2422 (2023)
Human glioblastoma multiforme (GBM) is a primary malignant brain tumor, a radically incurable disease characterized by rapid growth resistance to classical therapies, with a median patient survival of about 15 months. For decades, a plethora of appro
Externí odkaz:
https://doaj.org/article/0450b0c4a0654c3696b90b4dd4183cba
Autor:
Vladislav I. Rabinovich, Roman V. Mednikov, Svetlana N. Kizlo, Nikolai A. Belyakov, Alexey A. Sokolov
Publikováno v:
Therapeutic Apheresis and Dialysis. 20:413-419
One of the main causes of mortality of human immunodeficiency virus (HIV)-infected patients are complications of chronic hepatitis C virus (HCV). Combining drug therapy for HCV with double filtration plasmapheresis (DFPP) has significantly increased
Autor:
Roman V, Mednikov, Vladislav I, Rabinovich, Svetlana N, Kizlo, Nikolai A, Belyakov, Alexey A, Sokolov
Publikováno v:
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 20(4)
One of the main causes of mortality of human immunodeficiency virus (HIV)-infected patients are complications of chronic hepatitis C virus (HCV). Combining drug therapy for HCV with double filtration plasmapheresis (DFPP) has significantly increased